Personalized biologic selection for adults with psoriasis and psoriatic arthritis with cardiovascular biomarker testing
A Multi-center RCT Clinical Trial on Personalized Precision Medicine for Patients With Psoriasis and Psoriatic Arthritis and Investigation on Cardiovascular Biomarkers
This project will test whether a prescreen strategy can help doctors pick the most effective biologic medicine for adults (18–75) with psoriasis or psoriatic arthritis.
Quick facts
| Phase | Phase 4 |
|---|---|
| Study type | Interventional |
| Enrollment | 50 (estimated) |
| Ages | 18 Years to 75 Years |
| Sex | All |
| Sponsor | Taichung Veterans General Hospital Academic / other |
| Drugs / interventions | adalimumab, golimumab, certolizumab, ustekinumab, ixekizumab, secukinumab, guselkumab, risankizumab |
| Locations | 2 sites (Taichung, Taiwan and 1 other locations) |
| Trial ID | NCT07149792 on ClinicalTrials.gov |
What this trial studies
Forty adult patients with psoriasis, with or without psoriatic arthritis, were enrolled at multiple tertiary hospitals in Taiwan and randomized to either a prescreen strategy–based biologic selection group or a standard-based biologic selection group. Patients are followed through scheduled visits up to week 72, with possible extension to three years, and clinical endpoints include PASI as well as painful and swollen joint counts. The protocol also collects blood to isolate PBMCs, exposes them to Streptococcus pyogenes with and without a panel of biologics at trough-equivalent concentrations, and measures cytokine responses alongside cardiovascular biomarkers. The combined clinical and laboratory approach aims to link prescreen biomarker signals to real-world treatment responses.
Who should consider this trial
Good fit: Adults aged 18–75 with dermatologist-confirmed psoriasis or rheumatologist-confirmed psoriatic arthritis who can provide blood samples and do not have active infection, recent serious infection hospitalization, current cancer, or HIV are ideal candidates.
Not a fit: Patients with active infections, suspected or current malignancy, HIV infection, recent hospitalization for infection, or those unwilling/unable to provide blood samples are unlikely to receive benefit from this protocol.
Why it matters
Potential benefit: If successful, this approach could help match patients to biologics that control skin and joint symptoms more effectively and may identify signals related to cardiovascular risk.
How similar studies have performed: Precision prescreening to guide biologic choice has shown some promising pilot data but remains relatively novel and not yet widely validated for psoriasis and psoriatic arthritis.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Healthy subjects * Psoriasis patients * Psoriatic arthritis patients * Agree to provide a blood sample Exclusion Criteria: * A current history of cancer, * Recent hospitalization for infection or current antibiotic treatment * HIV infection.
Where this trial is running
Taichung, Taiwan and 1 other locations
- Taichung Veterans Hospital — Taichung, Taiwan, Taiwan (Not_yet_recruiting)
- Taichung Vertenans General Hospital — Taichung, Taiwan, Taiwan (Recruiting)
Study contacts
- Study coordinator: James Yen, MD PhD
- Email: vernayen@yahoo.com.tw
- Phone: 886-4-23592525
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.